SI3679946T1 - Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom - Google Patents

Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom

Info

Publication number: SI3679946T1
Authority: SI; Slovenia
Prior art keywords: tryptophan; tyrosine; formulation stabilized; neurotoxin formulation; liquid
Prior art date: 2016-05-27

Application number

SI201731069T

Other languages

English (en)

Inventor

Anders Jarstad

Anna Friis

Ulf Stahl

Ann Gurell

Barbro Agren

Emilia Edstrom

Andrew Pickett

Original Assignee

Ipsen Biopharma Limited

Galderma Holding SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-27

Filing date

2017-05-26

Publication date

2022-04-29

2017-05-26 Application filed by Ipsen Biopharma Limited, Galderma Holding SA filed Critical Ipsen Biopharma Limited

2022-04-29 Publication of SI3679946T1 publication Critical patent/SI3679946T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Birds (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gerontology & Geriatric Medicine (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Toxicology (AREA)
Medicinal Preparation (AREA)

SI201731069T 2016-05-27 2017-05-26 Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom SI3679946T1 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2016062085		2016-05-27
EP20152386.7A EP3679946B1 (en)	2016-05-27	2017-05-26	Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

Publications (1)

Publication Number	Publication Date
SI3679946T1 true SI3679946T1 (sl)	2022-04-29

Family

ID=56289455

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201731069T SI3679946T1 (sl)	2016-05-27	2017-05-26	Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom
SI201730582T SI3463432T1 (sl)	2016-05-27	2017-05-26	Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI201730582T SI3463432T1 (sl)	2016-05-27	2017-05-26	Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom

Country Status (31)

Country	Link
US (5)	US20190183988A1 (sl)
EP (3)	EP3679946B1 (sl)
JP (1)	JP7053498B2 (sl)
KR (2)	KR102399451B1 (sl)
CN (2)	CN111701010B (sl)
AR (1)	AR108631A1 (sl)
AU (1)	AU2017270359B2 (sl)
BR (1)	BR112018074311A2 (sl)
CA (1)	CA3025437A1 (sl)
CY (2)	CY1124237T1 (sl)
DK (3)	DK4026532T3 (sl)
EA (1)	EA038124B1 (sl)
ES (2)	ES2911124T3 (sl)
GE (1)	GEP20207139B (sl)
HR (2)	HRP20220024T1 (sl)
HU (2)	HUE057640T2 (sl)
IL (2)	IL285190B (sl)
LT (2)	LT3463432T (sl)
MX (1)	MX392529B (sl)
PL (2)	PL3679946T3 (sl)
PT (2)	PT3463432T (sl)
RS (2)	RS62832B1 (sl)
RU (1)	RU2741497C9 (sl)
SA (1)	SA518400513B1 (sl)
SG (1)	SG11201810561YA (sl)
SI (2)	SI3679946T1 (sl)
SM (2)	SMT202200080T1 (sl)
TW (1)	TWI777955B (sl)
UA (1)	UA123679C2 (sl)
WO (1)	WO2017203038A1 (sl)
ZA (1)	ZA201807904B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8168206B1 (en)	2005-10-06	2012-05-01	Allergan, Inc.	Animal protein-free pharmaceutical compositions
SG10201405582YA (en)	2008-12-31	2014-10-30	Revance Therapeutics Inc	Injectable Botulinum Toxin Formulations
KR102192618B1 (ko)	2009-06-25	2020-12-17	레반스 테라퓨틱스, 아이엔씨.	알부민불포함 보툴리눔 독소 제제
US9480731B2 (en)	2013-12-12	2016-11-01	Medy-Tox, Inc.	Long lasting effect of new botulinum toxin formulations
CN117959415A (zh)	2016-09-13	2024-05-03	阿勒根公司	非蛋白质梭菌毒素组合物
AU2018389121A1 (en) *	2017-12-20	2020-07-30	Allergan, Inc.	Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders
UY38744A (es) *	2019-06-07	2020-12-31	Nestle Skin Health S A	Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
CN116440281A (zh) *	2022-01-07	2023-07-18	重庆誉颜制药有限公司	一种肉毒毒素蛋白组合物
TW202333767A (zh)	2022-01-14	2023-09-01	英商益普生生物製藥有限公司	中度至極重度眉間紋及眼角外紋之治療
WO2023156389A1 (en)	2022-02-15	2023-08-24	Merz Pharma Gmbh & Co. Kgaa	Liquid botulinum toxin formulation and use thereof
AR133528A1 (es)	2023-08-10	2025-10-08	Merz Pharma Gmbh & Co Kgaa	Formulación líquida de toxina botulínica y su uso

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI240627B (en) *	1996-04-26	2005-10-01	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
ES2275992T5 (es)	2000-02-08	2011-05-18	Allergan, Inc.	Composiciones farmacéuticas de toxina botulínica.
US20030118598A1 (en) *	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) *	2000-02-08	2006-11-30	Allergan, Inc.	Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
EP1260230A4 (en) *	2000-02-29	2008-08-06	Chugai Pharmaceutical Co Ltd	LONG-TERM STABILIZED PREPARATIONS
US6627602B2 (en) *	2001-11-13	2003-09-30	Duke University	Preventing desensitization of receptors
DE10333317A1 (de)	2003-07-22	2005-02-17	Biotecon Therapeutics Gmbh	Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en)	2004-07-12	2006-01-18	Ipsen Ltd	Botulinum neurotoxin composition
KR100852824B1 (ko) *	2004-07-26	2008-08-18	메르츠 파마 게엠베하 운트 코. 카가아	보툴리눔 신경독소를 포함하는 치료 조성물
WO2006013370A1 (en) *	2004-08-04	2006-02-09	Ipsen Limited	Pharmaceutical composition containing botulinum neurotoxin a2
US20080220021A1 (en)	2005-02-14	2008-09-11	Pankaj Modi	Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
FR2902341B1 (fr)	2006-06-16	2011-02-25	Scras	Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
CA2690773C (en) *	2007-07-10	2013-09-17	Medy-Tox, Inc.	Pharmaceutical liquid composition of botulinum toxin with improved stability
US9107815B2 (en)	2008-02-22	2015-08-18	Allergan, Inc.	Sustained release poloxamer containing pharmaceutical compositions
EP2480250B1 (en)	2009-09-24	2014-04-16	Allergan, Inc.	Compositions comprising botulinum toxin A or B for use in the treatment of osteoporosis
KR101679370B1 (ko)	2011-06-01	2016-11-24	바이오메디슨, 인코퍼레이티드	비-ｆｒｅｔ 보툴리눔 검정법
RU2616281C2 (ru)	2011-09-29	2017-04-13	СЕЛЛСНЭП, ЭлЭлСи	Композиции и способы испытаний на токсикогенность
KR101357999B1 (ko) *	2012-03-20	2014-02-03	함종욱	보툴리눔 에이형 독소의 액상제품
WO2015044416A1 (en)	2013-09-30	2015-04-02	Galderma S.A.	Prostate cancer treatment
GB201407525D0 (en) *	2014-04-29	2014-06-11	Syntaxin Ltd	Manufacture of recombinant clostridium botulinum neurotoxins

2017
- 2017-05-26 RU RU2018142149A patent/RU2741497C9/ru active
- 2017-05-26 EP EP20152386.7A patent/EP3679946B1/en active Active
- 2017-05-26 ES ES20152386T patent/ES2911124T3/es active Active
- 2017-05-26 HR HRP20220024TT patent/HRP20220024T1/hr unknown
- 2017-05-26 CN CN202010742639.2A patent/CN111701010B/zh active Active
- 2017-05-26 RS RS20220045A patent/RS62832B1/sr unknown
- 2017-05-26 PL PL20152386T patent/PL3679946T3/pl unknown
- 2017-05-26 BR BR112018074311A patent/BR112018074311A2/pt unknown
- 2017-05-26 HU HUE20152386A patent/HUE057640T2/hu unknown
- 2017-05-26 LT LTEP17728095.5T patent/LT3463432T/lt unknown
- 2017-05-26 SM SM20220080T patent/SMT202200080T1/it unknown
- 2017-05-26 SG SG11201810561YA patent/SG11201810561YA/en unknown
- 2017-05-26 SI SI201731069T patent/SI3679946T1/sl unknown
- 2017-05-26 TW TW106117499A patent/TWI777955B/zh active
- 2017-05-26 PL PL17728095T patent/PL3463432T3/pl unknown
- 2017-05-26 UA UAA201811606A patent/UA123679C2/uk unknown
- 2017-05-26 DK DK21211390.6T patent/DK4026532T3/da active
- 2017-05-26 US US16/304,986 patent/US20190183988A1/en not_active Abandoned
- 2017-05-26 EP EP21211390.6A patent/EP4026532B1/en active Active
- 2017-05-26 SM SM20210003T patent/SMT202100003T1/it unknown
- 2017-05-26 SI SI201730582T patent/SI3463432T1/sl unknown
- 2017-05-26 PT PT177280955T patent/PT3463432T/pt unknown
- 2017-05-26 HU HUE17728095A patent/HUE052023T2/hu unknown
- 2017-05-26 WO PCT/EP2017/062785 patent/WO2017203038A1/en not_active Ceased
- 2017-05-26 GE GEAP201714939A patent/GEP20207139B/en unknown
- 2017-05-26 AU AU2017270359A patent/AU2017270359B2/en active Active
- 2017-05-26 JP JP2018562171A patent/JP7053498B2/ja active Active
- 2017-05-26 IL IL285190A patent/IL285190B/en unknown
- 2017-05-26 HR HRP20202070TT patent/HRP20202070T1/hr unknown
- 2017-05-26 EA EA201892493A patent/EA038124B1/ru unknown
- 2017-05-26 CA CA3025437A patent/CA3025437A1/en active Pending
- 2017-05-26 LT LTEP20152386.7T patent/LT3679946T/lt unknown
- 2017-05-26 CN CN201780044565.1A patent/CN109562148A/zh active Pending
- 2017-05-26 KR KR1020187037095A patent/KR102399451B1/ko active Active
- 2017-05-26 RS RS20201596A patent/RS61340B1/sr unknown
- 2017-05-26 EP EP17728095.5A patent/EP3463432B1/en active Active
- 2017-05-26 DK DK17728095.5T patent/DK3463432T3/da active
- 2017-05-26 KR KR1020227012437A patent/KR102423739B1/ko active Active
- 2017-05-26 PT PT201523867T patent/PT3679946T/pt unknown
- 2017-05-26 ES ES17728095T patent/ES2846350T3/es active Active
- 2017-05-26 MX MX2018014631A patent/MX392529B/es unknown
- 2017-05-26 DK DK20152386.7T patent/DK3679946T3/da active
- 2017-05-29 AR ARP170101464A patent/AR108631A1/es active IP Right Grant
2018
- 2018-11-21 IL IL263173A patent/IL263173B/en unknown
- 2018-11-22 ZA ZA2018/07904A patent/ZA201807904B/en unknown
- 2018-11-26 SA SA518400513A patent/SA518400513B1/ar unknown
2021
- 2021-01-05 CY CY20211100001T patent/CY1124237T1/el unknown
- 2021-06-28 US US17/304,888 patent/US20230190892A9/en not_active Abandoned
2022
- 2022-01-25 CY CY20221100057T patent/CY1124916T1/el unknown
2023
- 2023-02-24 US US18/173,991 patent/US20230181702A1/en not_active Abandoned
- 2023-09-28 US US18/476,731 patent/US12285468B2/en active Active
2025
- 2025-04-25 US US19/189,864 patent/US20250255943A1/en active Pending

Also Published As

Publication number	Publication date
AU2017270359B2 (en)	2023-09-21
PT3679946T (pt)	2022-01-14
MX2018014631A (es)	2019-06-12
SA518400513B1 (ar)	2022-11-03
CN109562148A (zh)	2019-04-02
ES2911124T3 (es)	2022-05-17
ES2846350T3 (es)	2021-07-28
EP4026532B1 (en)	2025-11-26
TW201742632A (zh)	2017-12-16
SI3463432T1 (sl)	2021-02-26
EA038124B1 (ru)	2021-07-09
TWI777955B (zh)	2022-09-21
US20190183988A1 (en)	2019-06-20
MX392529B (es)	2025-03-21
SMT202100003T1 (it)	2021-03-15
EA201892493A1 (ru)	2019-04-30
US20230190892A9 (en)	2023-06-22
HUE057640T2 (hu)	2022-05-28
LT3463432T (lt)	2021-01-25
IL263173B (en)	2021-08-31
DK4026532T3 (da)	2025-12-08
PL3679946T3 (pl)	2022-05-30
HRP20202070T1 (hr)	2021-02-19
HUE052023T2 (hu)	2021-04-28
RU2018142149A (ru)	2020-06-29
ZA201807904B (en)	2020-05-27
US20210330765A1 (en)	2021-10-28
KR102423739B1 (ko)	2022-07-21
PL3463432T3 (pl)	2021-04-19
RU2741497C2 (ru)	2021-01-26
US20250255943A1 (en)	2025-08-14
DK3679946T3 (da)	2022-02-07
LT3679946T (lt)	2022-02-10
EP3463432A1 (en)	2019-04-10
JP7053498B2 (ja)	2022-04-12
BR112018074311A2 (pt)	2019-10-01
SMT202200080T1 (it)	2022-03-21
UA123679C2 (uk)	2021-05-12
CA3025437A1 (en)	2017-11-30
RS62832B1 (sr)	2022-02-28
US12285468B2 (en)	2025-04-29
US20230181702A1 (en)	2023-06-15
EP4026532A1 (en)	2022-07-13
CN111701010B (zh)	2023-09-26
IL263173A (en)	2018-12-31
WO2017203038A1 (en)	2017-11-30
EP3463432B1 (en)	2020-10-07
IL285190A (en)	2021-08-31
EP3679946A1 (en)	2020-07-15
EP3679946B1 (en)	2022-01-05
SG11201810561YA (en)	2018-12-28
CN111701010A (zh)	2020-09-25
AR108631A1 (es)	2018-09-12
CY1124237T1 (el)	2022-07-22
RS61340B1 (sr)	2021-02-26
NZ748626A (en)	2025-05-02
JP2019517481A (ja)	2019-06-24
CY1124916T1 (el)	2023-01-05
KR102399451B1 (ko)	2022-05-23
US20240050539A1 (en)	2024-02-15
DK3463432T3 (da)	2021-01-04
PT3463432T (pt)	2021-01-12
HRP20220024T1 (hr)	2022-04-01
RU2741497C9 (ru)	2021-04-30
RU2018142149A3 (sl)	2020-07-23
KR20190022548A (ko)	2019-03-06
GEP20207139B (en)	2020-07-27
KR20220054887A (ko)	2022-05-03
AU2017270359A1 (en)	2018-12-13
IL285190B (en)	2022-07-01

Publication	Publication Date	Title
IL285190A (en)	2021-08-31	A liquid neurotoxin preparation stabilized by tryptophan or tyrosine
SG11202003754YA (en)	2020-05-28	High concentration protein formulations with reduced viscosity
ZA201901590B (en)	2020-10-28	Liquid pharmaceutical composition
GB201520014D0 (en)	2015-12-30	Liquid formulation
IL263630A (en)	2019-01-31	A stable liquid pharmaceutical preparation
SG10202012083YA (en)	2021-01-28	Liquid delivery system
ZA201901736B (en)	2020-11-25	Liquid pharmaceutical composition
SI3496551T1 (sl)	2025-02-28	Tekoča alulozna sestava
PT3334747T (pt)	2023-12-12	Formulação de gonadotrofina líquida estável
EP3395325A4 (en)	2019-07-31	LIQUID COSMETIC COMPOSITION
SI3261676T1 (sl)	2020-10-30	Formulacije tekočega levotiroksina
PL3791860T3 (pl)	2024-03-18	Stabilna ciekła formulacja gonadotropiny
ZA201806530B (en)	2019-07-31	Phosphaplatin liquid formulations
EP3305296A4 (en)	2019-02-13	AQUEOUS LIQUID FORMULATION
HUE064272T2 (hu)	2024-03-28	Illékony folyadékadagoló rendszer
GB201505051D0 (en)	2015-05-06	Liquid formulation
EP3505760A4 (en)	2020-01-22	FLUID DELIVERY SYSTEM
GB201612441D0 (en)	2016-08-31	Liquid creatine
GB201607730D0 (en)	2016-06-15	Liquid lighters